Table 1.
Baseline characteristics and clinical response to sunitinib treatment in patients with imatinib-resistant GIST
| Characteristic | All patients (N = 97), n (%) |
|---|---|
| Sex | |
| Male | 64 (66) |
| Female | 33 (34) |
| Age (y) | |
| Median | 55 |
| Range | 26–76 |
| ECOG performance status | |
| 0 | 50 (52) |
| 1 | 41 (42) |
| 2 | 6 (6) |
| Time since original diagnosis (mo) | |
| Median | 33 |
| Range | 5–212 |
| Most common sites of metastatic GIST at study entry | |
| Liver | 91 (94) |
| Soft tissue | 43 (44) |
| Peritoneum | 42 (43) |
| Total no. metastatic sites | |
| 1 | 5 (5) |
| 2 | 17 (18) |
| ≥3 | 75 (77) |
| Reason for discontinuing imatinib | |
| Tumor progression | 93 (96) |
| Intolerance | 4 (4) |
| Maximum daily dose of prior imatinib (mg) | |
| Median | 600 |
| Range | 400–1,000 |
| Duration of prior imatinib treatment (mo) | |
| Median | 19 |
| Range | 2–38 |
| Starting sunitinib dosing schedule | |
| 25 mg (Schedule 2/2) | 6 (6) |
| 50 mg (Schedule 2/2) | 23 (24) |
| 50 mg (Schedule 4/2) | 55 (57) |
| 50 mg (Schedule 2/1) | 9 (9) |
| 75 mg (Schedule 2/2) | 4 (4) |
| Tumor response to sunitinib | |
| CR | 0 (0) |
| PR | 7 (7) |
| SD | 73 (75) |
| ≥6 mo | 28 (29) |
| PD | 6 (6) |
| Not evaluable or missing | 11 (11) |
| Clinical benefit* | 35 (36) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*
Defined as CR, PR, or SD ≥6 mo.